» Articles » PMID: 20063113

Expression of D2RmRNA Isoforms and ERmRNA Isoforms in Prolactinomas: Correlation with the Response to Bromocriptine and with Tumor Biological Behavior

Overview
Journal J Neurooncol
Publisher Springer
Date 2010 Jan 12
PMID 20063113
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Invasive prolactinomas are more likely to be resistant to drug therapy but the mechanism of this is still unknown. The objective of this study was to analyze the different expression of ERmRNA and D2RmRNA isoforms in prolactinomas responsive and resistant to dopamine agonist (DA), and to discuss the correlation of such gene expression with tumor biological behavior. A prospective study of 20 consecutive patients who harbored prolactinomas was designed. Patients were classified as responsive (14 cases) or resistant (six cases) according to their clinical and biochemical response to bromocriptine. Tumor tissue samples were examined by means of QRT-PCR analysis. Median D2SmRNA expression in responsive patients was about 2.5-fold that in resistant ones (13.5 +/- 10.4 and 5.4 +/- 2.4, respectively, P = 0.09). No significant difference was found between D2LmRNA expression levels (P = 0.77). However, there was a significant difference between D2S/D2LmRNA ratios for responsive and resistant tumors (P = 0.012). A significant difference was not found between these two groups in levels of ERalphamRNA and ERbetamRNA expression (P = 0.20 and 0.06, respectively). D2SmRNA expression was significantly different for invasive and noninvasive tumors (6.2 +/- 3.6 vs. 17.0 +/- 11.2, respectively, P = 0.02). The D2S/D2L ratio is related to the responsiveness of prolactinomas to DA medication, in which D2SmRNA plays an important role. Lower expression of D2SmRNA in invasive tumor patients suggests that invasive prolactinomas may be more likely to be resistant to DA medication.

Citing Articles

Dopamine agonist therapy for prolactinomas: do we need to rethink the place of surgery in prolactinoma management?.

De Sousa S Endocr Oncol. 2023; 2(1):R31-R50.

PMID: 37435462 PMC: 10259306. DOI: 10.1530/EO-21-0038.


Macroprolactinoma with secondary resistance to dopamine agonists: a case report and review of the literature.

Tng E, Teo A, Aung A J Med Case Rep. 2023; 17(1):96.

PMID: 36927797 PMC: 10021939. DOI: 10.1186/s13256-023-03820-5.


DRD2 expression based on F-fallypride PET/MR predicts the dopamine agonist resistance of prolactinomas: a pilot study.

Tang H, Cheng Y, Lou X, Yao H, Xie J, Gu W Endocrine. 2023; 80(2):419-424.

PMID: 36689171 DOI: 10.1007/s12020-023-03310-0.


Transcriptomic Profiles of Normal Pituitary Cells and Pituitary Neuroendocrine Tumor Cells.

Oh J, Osorio R, Jung J, Carrete L, Choudhary N, Lad M Cancers (Basel). 2023; 15(1).

PMID: 36612109 PMC: 9817686. DOI: 10.3390/cancers15010110.


Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms.

Pivonello C, Patalano R, Negri M, Pirchio R, Colao A, Pivonello R Front Endocrinol (Lausanne). 2022; 12:791633.

PMID: 35095761 PMC: 8789681. DOI: 10.3389/fendo.2021.791633.


References
1.
Hamilton D, Vance M, Boulos P, Laws E . Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists. Pituitary. 2006; 8(1):53-60. DOI: 10.1007/s11102-005-5086-1. View

2.
Hayes G, Biden T, Selbie L, Shine J . Structural subtypes of the dopamine D2 receptor are functionally distinct: expression of the cloned D2A and D2B subtypes in a heterologous cell line. Mol Endocrinol. 1992; 6(6):920-6. DOI: 10.1210/mend.6.6.1323056. View

3.
S Pereira-Lima J, Marroni C, Pizarro C, Barbosa-Coutinho L, Ferreira N, Oliveira M . Immunohistochemical detection of estrogen receptor alpha in pituitary adenomas and its correlation with cellular replication. Neuroendocrinology. 2004; 79(3):119-24. DOI: 10.1159/000077269. View

4.
Gillam M, Molitch M, Lombardi G, Colao A . Advances in the treatment of prolactinomas. Endocr Rev. 2006; 27(5):485-534. DOI: 10.1210/er.2005-9998. View

5.
Di Sarno A, Landi M, Cappabianca P, Di Salle F, Rossi F, Pivonello R . Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab. 2001; 86(11):5256-61. DOI: 10.1210/jcem.86.11.8054. View